All In Biotech

BLA 021536 · Novo Nordisk INC

Levemir Flextouch

Insulin Detemir Recombinant · Subcutaneous

Novel

Last checked: Nov 20, 2026Latest source record: Dec 8, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Jun 16, 2005

Approved uses

4

Original approval plus efficacy supplements

Registered trials

0

0 Phase 3, 0 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 9, 2024.

LEVEMIR is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. Limitations of Use LEVEMIR is not recommended for the treatment of diabetic ketoacidosis. LEVEMIR is a long-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus ( 1 ). Limitations of Use: Not recommended for the treatment of diabetic ketoacidosis.

Mechanism: The primary activity of insulin, including LEVEMIR, is regulation of glucose metabolism. Insulins and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin also inhibits lipolysis and proteolysis, and enhances protein synthesis.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • LEVEMIR FLEXTOUCH · INSULIN DETEMIR RECOMBINANT 300 UNITS/3ML (100 UNITS/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
  • LEVEMIR INNOLET · INSULIN DETEMIR RECOMBINANT 300 UNITS/3ML (100 UNITS/ML) · INJECTABLE, SUBCUTANEOUS · Discontinued
  • LEVEMIR · INSULIN DETEMIR RECOMBINANT 1000 UNITS/10ML (100 UNITS/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
  • LEVEMIR PENFILL · INSULIN DETEMIR RECOMBINANT 300 UNITS/3ML (100 UNITS/ML) · INJECTABLE, SUBCUTANEOUS · Discontinued
  • LEVEMIR FLEXPEN · INSULIN DETEMIR RECOMBINANT 300 UNITS/3ML (100 UNITS/ML) · INJECTABLE, SUBCUTANEOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Detemir Recombinant" as an intervention, any sponsor and status, largest first.

All 0 trials

No registered drug trials name this ingredient.

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Levemir (Insulin Detemir)

2024 spending

$30.6M

Beneficiaries

48,292

142,657 claims

Per beneficiary

$634

$10.38 per unit

View as table
YearSpending
2020$436,907,523
2021$373,910,077
2022$319,727,025
2023$287,253,250
2024$30,621,217

Part D: Levemir Flexpen (Insulin Detemir)

2024 spending

$121M

Beneficiaries

210,817

559,470 claims

Per beneficiary

$575

$10.05 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$1,025,556,477
2024$121,306,539

Part D: Levemir Flextouch (Insulin Detemir)

2024 spending

$957K

Beneficiaries

3,073

5,655 claims

Per beneficiary

$311

$10.46 per unit

View as table
YearSpending
2020$1,554,791,325
2021$1,495,189,258
2022$1,408,211,049
2023$184,280,489
2024$956,769

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Novo Nordisk · Also marketed as Levemir Innolet, Levemir, Levemir Penfill, Levemir Flexpen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.